Stordahl Capital Management Inc. Purchases New Shares in Omeros Co. (NASDAQ:OMER)

Stordahl Capital Management Inc. purchased a new stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 40,000 shares of the biopharmaceutical company's stock, valued at approximately $395,000. Stordahl Capital Management Inc. owned about 0.07% of Omeros as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. MML Investors Services LLC boosted its holdings in shares of Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 3,000 shares during the last quarter. State Street Corp boosted its holdings in shares of Omeros by 0.3% in the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock worth $4,867,000 after buying an additional 3,839 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock worth $235,000 after buying an additional 4,000 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Omeros by 21.2% in the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company's stock worth $241,000 after buying an additional 4,257 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Omeros by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company's stock worth $5,318,000 after buying an additional 6,839 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Rodman & Renshaw started coverage on shares of Omeros in a research note on Thursday, November 14th. They set a "buy" rating and a $9.00 target price on the stock. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Friday, January 17th. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research note on Thursday, January 16th. Finally, RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Omeros currently has an average rating of "Moderate Buy" and an average price target of $22.50.

Omeros Stock Performance

Shares of Omeros stock traded down $0.19 on Monday, hitting $8.43. 323,683 shares of the company traded hands, compared to its average volume of 546,985. The stock has a market capitalization of $488.52 million, a P/E ratio of -3.65 and a beta of 1.98. Omeros Co. has a 52 week low of $2.61 and a 52 week high of $13.60. The business has a 50-day simple moving average of $9.87 and a 200 day simple moving average of $6.35.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.